Beam Therapeutics Inc.
BEAM-304
phenylketonuria
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for BEAM-304 in phenylketonuria are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Beam expects to report initial clinical data in 2026.”